ArticleFrontiers in endocrinology2025
Inverse association between remnant cholesterol and risks of atrial fibrillation among patients with type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between C-reactive protein to triglyceride-glucose index and atrial fibrillation: a cross-sectional analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to investigate the association between remnant cholesterol (RC) levels and the risk of atrial fibrillation (AF) among patients with type 2 diabetes, by leveraging data from a large cohort of diabetic patients. Methods: We included patients with T2DM who received routine care at the affiliated hospital of Qingdao University between January 2014 and December 2023. A total of 9930 patients remained eligible for the final analysis. The primary outcome of this study was the incidence of atrial fibrillation. Results: During a mean follow up of 6.12 ± 2.75 years, a total of 1,028 AF events occurred. Cox proportional hazards regression was performed to obtain the hazard ratios (HRs) for the incidence of atrial fibrillation by different RC levels at baseline. Compared to Q1, the age- and sex-adjusted HRs for coronary artery disease were 0.89 (95% CI: 0.80-1.28) in Q2, 0.88 (95% CI: 0.80-0.98) in Q3, and 0.76 (95% CI: 0.67-0.84) in Q4. As a continuous variable, RC had an HR of 0.77 (95% CI: 0.64-0.93). After adjusting for age, sex, systolic blood pressure, triglycerides, HbA1c, smoking status, eGFR, and the use of antiplatelet or anticoagulant, lipid-lowering, antihypertensive, and glucose-lowering medications, the multivariable-adjusted HRs were 0.92 (95% CI: 0.82-1.32) in Q2, 0.97 (95% CI: 0.88-1.08) in Q3, and 0.88 (95% CI: 0.79-0.98) in Q4. As a continuous variable, RC had an HR of 0.83 (95% CI: 0.66-0.99). Conclusions: We demonstrated an inverse association between RC and incident risk of AF using data from real world retrospectively. Future prospective studies with the best option of an interventional trial are needed to further validate our findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.